InstalabLoading...
InstalabLoading...
Colorectal cancer is one of the most preventable cancers, yet it remains the second leading cause of cancer death in many countries. The reason for that gap is simple: most people never get screened. FIT (fecal immunochemical test) exists to close it. This stool test detects microscopic amounts of human blood that you cannot see, the kind of low-grade bleeding that polyps and early-stage cancers produce long before you notice any symptoms.
At standard screening thresholds, a single FIT catches roughly 79 to 90% of colorectal cancers and correctly clears about 94% of people who do not have cancer. When the result comes back negative at a low threshold, the probability that you currently have colorectal cancer drops to roughly 0.1 to 0.2%. That combination of simplicity, accuracy, and a sample you collect at home is why every major screening guideline now lists annual FIT as a frontline option.
FIT uses antibodies that specifically recognize the globin portion of human hemoglobin, the oxygen-carrying protein inside your red blood cells. When a polyp, tumor, or inflamed patch in your colon bleeds even slightly, some of that blood mixes into your stool. FIT picks it up at concentrations far below anything visible to the eye.
This makes it fundamentally different from the older guaiac-based fecal occult blood test (gFOBT), which reacted to peroxidase activity from many sources, including rare meats and certain vegetables. Because FIT targets only human hemoglobin, you do not need any dietary restrictions before testing. Large comparative studies consistently show FIT has higher sensitivity, at least equal specificity, and better participation rates than gFOBT, because it requires just one stool sample instead of three.
One practical detail: because FIT targets intact hemoglobin protein, it is most sensitive to bleeding from your lower digestive tract (colon and rectum). Blood from the stomach or upper intestine gets partially digested during transit, so FIT may miss upper GI sources of bleeding. This test is designed for colorectal screening, not for evaluating all sources of GI blood loss.
FIT's accuracy depends heavily on the hemoglobin threshold your lab or screening program uses to define a positive result. Lower thresholds catch more cancers but also flag more people who turn out not to have cancer, increasing the number of follow-up colonoscopies needed. The table below summarizes performance at commonly used cutoffs from large meta-analyses and cohort studies.
| Setting | Sensitivity for Colorectal Cancer | Specificity |
|---|---|---|
| Average-risk screening (cutoff 10 to 20 µg/g) | 79 to 91% | 91 to 95% |
| Higher-risk populations (cutoff 15 to 25 µg/g) | About 93% | 91 to 94% |
| Symptomatic patients (cutoff 10 µg/g) | 89 to 97% | 65 to 86% |
Those numbers look strong for cancer, but FIT is far less sensitive for pre-cancerous growths called advanced adenomas, the large polyps that have not yet become cancer. At standard cutoffs, FIT catches only about 25 to 45% of advanced adenomas. This is why a negative FIT does not mean your colon is entirely clear. It means you are very unlikely to have cancer right now. Polyps that are not yet bleeding can still be present.
FIT also detects cancers at different stages with slightly different reliability. A large meta-analysis of 44 studies and over 92,000 participants found pooled sensitivities of about 73% for stage I, 80% for stage II, 82% for stage III, and 79% for stage IV colorectal cancer. Earlier-stage and smaller tumors bleed less consistently, which is exactly why annual retesting matters.
The real question is not just whether FIT finds cancer on a single test, but whether using it regularly saves lives. The answer from large national screening programs is clear.
Taiwan's One Million FIT program, which invited over 5.4 million adults to biennial screening, found that FIT-based screening reduced colorectal cancer mortality by about 40% among those who participated (adjusted rate ratio 0.60). The benefit was especially strong for cancers in the left side of the colon and rectum. An Italian program covering over one million adults showed similar results: a 33% reduction in colorectal cancer incidence (adjusted rate ratio 0.67 in men, 0.79 in women) and a 54 to 65% reduction in colorectal cancer mortality among screening participants.
Timing after a positive result matters enormously. In a study of over 204,000 US veterans with an abnormal FIT, those who waited more than 19 months for a follow-up colonoscopy had about 50% higher colorectal cancer mortality (hazard ratio 1.52) compared to those who had colonoscopy within one to three months. In a Chinese cohort of over 74,000 FIT-positive adults, those who did not follow through with colonoscopy had 85% higher colorectal cancer mortality (hazard ratio 1.85) over 10 years. A positive FIT without timely colonoscopy erases the survival benefit of screening.
Emerging research suggests that occult blood in stool is not just a cancer marker. It may also reflect broader vascular and inflammatory health. A nationwide Korean study of over 6.2 million adults found that a positive FIT was associated with about 9% higher risk of ischemic stroke (adjusted hazard ratio 1.09), 9% higher risk of heart attack (adjusted hazard ratio 1.09), and 15% higher all-cause mortality (adjusted hazard ratio 1.15), even after excluding people with colorectal cancer and adjusting for smoking, diabetes, blood pressure, cholesterol, and BMI.
A Danish cohort followed for 33 years found similar patterns: people who ever tested positive on a fecal occult blood test had about 20% higher non-cancer death rates and 22% higher cardiovascular death rates compared to those who always tested negative. A Taiwanese cohort of over 546,000 adults followed up to 26 years found that each additional 10 µg of hemoglobin per gram of stool above the positivity threshold was linked to roughly 4% higher all-cause mortality. These effects are modest but consistent, suggesting that microscopic intestinal bleeding tracks with systemic inflammation or vascular disease beyond the colon.
This does not mean a positive FIT should trigger a cardiology workup. But it does mean that if your FIT is positive and colonoscopy finds no cancer, the finding still deserves attention. It may reflect chronic low-grade inflammation, mucosal injury, or vascular fragility that is worth discussing with your doctor.
FIT results are reported either as positive/negative or as a quantitative fecal hemoglobin concentration in micrograms of hemoglobin per gram of stool (µg Hb/g). Different screening programs and labs use different cutoffs to define a positive result, so your result should always be interpreted against the threshold your specific lab uses. The ranges below reflect commonly used tiers from published research and screening programs.
| Fecal Hemoglobin Level | What It Suggests |
|---|---|
| Undetectable (0 µg/g) | Very low near-term colorectal cancer risk. Repeatedly undetectable values across rounds indicate the lowest risk group. |
| Detectable but below cutoff (e.g., 1 to 9 µg/g at a 10 µg/g threshold) | Negative result by program criteria. Risk is still low, but higher than undetectable. Prior values in this range modestly increase predicted future risk of advanced neoplasia. |
| At or above program cutoff (10 to 20 µg/g in most programs) | Positive result. Colonoscopy is recommended. Probability of colorectal cancer at this level is roughly 3 to 8%. |
| High quantitative value (100+ µg/g) | Strongly positive. In one large pathway study, one-year cancer risk was about 17% at 100 µg/g or above. Urgent colonoscopy is appropriate. |
FIT brands are not interchangeable. A study comparing nine common quantitative FIT analyzers found that sensitivity for advanced neoplasia varied several-fold across devices, even at the same nominal cutoff. Comparing results between different labs or different FIT brands can be misleading. Always compare your results within the same testing system.
Because colorectal lesions bleed intermittently, a single negative FIT can miss a cancer that simply was not bleeding on the day you collected the sample. This intermittent bleeding is the single biggest source of false negatives and is the main reason annual retesting is recommended. Sensitivity for advanced adenomas (large polyps that have not yet become cancer) is only 25 to 45% on a single test, so a negative FIT should never be interpreted as proof that your colon is polyp-free.
Several medications and conditions can shift your result without indicating cancer:
FIT should not be used during active visible rectal bleeding, during hospitalization for acute illness, or as a way to evaluate iron-deficiency anemia. A systematic review found that FIT has poor sensitivity (about 58%) for identifying the causes of iron-deficiency anemia, and a negative FIT should not be used to skip endoscopy in someone being evaluated for anemia.
A single FIT is a snapshot. Because polyps and early cancers bleed intermittently, the test can be negative today and positive three months later from the same lesion. The real power of FIT comes from regular repetition: annual testing in the US, biennial in most European programs. Over multiple rounds, the cumulative sensitivity for catching a cancer before it becomes advanced rises dramatically.
A Dutch study of over 265,000 participants who tested negative across two screening rounds found that their prior fecal hemoglobin values, even though below the positive threshold, predicted their risk of advanced neoplasia at the next round. Those with the highest sub-threshold readings had roughly nine times the odds of advanced neoplasia compared to those with the lowest readings. This means your quantitative FIT value carries information even when the result is technically negative, and tracking it over time can reveal a trend before you cross into positive territory.
If you are using FIT for screening, get a baseline test now, then retest annually. If your quantitative value is rising over successive tests, even if still below the positive cutoff, that trend deserves a conversation about whether earlier colonoscopy is appropriate.
A negative FIT at a standard threshold is reassuring. Your near-term probability of having colorectal cancer is very low. Continue annual retesting and follow through on any age-appropriate colonoscopy schedule recommended by your doctor. If you have red-flag symptoms (unexplained weight loss, persistent change in bowel habits, visible blood in stool, or iron-deficiency anemia), a negative FIT alone is not enough to rule out a problem. Those symptoms warrant direct evaluation regardless of the FIT result.
A positive FIT requires colonoscopy. Not next year, not after a retest. Now. The data are unambiguous: delaying colonoscopy beyond a few months after a positive FIT increases the risk of being diagnosed with a later-stage cancer and increases cancer-specific mortality. In one large US study, delays beyond 19 months were associated with about 50% higher cancer death rates compared to colonoscopy within three months.
If colonoscopy after a positive FIT finds polyps, they will be removed during the procedure, and your gastroenterologist will set a surveillance schedule based on polyp type and number. If colonoscopy finds cancer, you will be staged and treated. If colonoscopy is completely normal, that is still useful information, but the positive FIT is worth noting in your records. People with a positive FIT and a clean colonoscopy still carry modestly higher risks of future cardiovascular events and all-cause mortality compared to people who always test negative, so continued attention to cardiovascular risk factors is reasonable.
Fecal Occult Blood (FIT) is best interpreted alongside these tests.